研究

Shiraishi N, Takahama T, Sakai K, Tanaka K, Nakagawa Y, Kanemura H, Nakayama T, Kawanaka Y, Kurosaki T, Suzuki S, Iwasa T, Tanizaki J, Inagaki C, Yonesaka K, Fukuoka K, Mitsudomi T, Nishio K, Hayashi H, Nakagawa K.

Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.

Kaneda H, Daga H, Okada A, Nakatani Y, Tani Y, Oka T, Sawa K, Sakai K, Nishio K, Kawaguchi T.

Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial.

Fujita Y, Matsuoka H, Chiba Y, Tsurutani J, Yoshida T, Sakai K, Nakura M, Sakamoto R, Makimura C, Ohtake Y, Tanaka K, Hayashi H, Takahama T, Tanizaki J, Koyama A, Nishio K, Nakagawa K.

Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain.

Kenmotsu H, Sakai K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Koyama R, Masuda K, Hayashi H, Toyozawa R, Miura S, Sato Y, Nakagawa K, Yamamoto N, Nishio K, Takahashi T.

Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study.

Hata A, Katakami N, Takase N, Kibata K, Yamanaka Y, Tamiya M, Mori M, Kijima T, Morita S, Sakai K, Nishio K.

Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.

Sakai K, Ohara S, Tanaka J, Suda K, Muramatsu T, Uematsu C, Tsutani Y, Mitsudomi T, Nishio K.

Improved platelet separation performance from whole blood using an acoustic fluidics system

De Velasco MA, Sakai K, Mitani S, Kura Y, Minamoto S, Haeno T, Hayashi H, Nishio K.

A machine learning-based method for feature reduction of methylation data for the classification of cancer tissue origin